(Nasdaq: COSM) Posted Record Revenue In Every 2026 Reporting Quarter So Far

Two agreements. Under two weeks.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored (Nasdaq: COSM) Posted Record Revenue In Every 2026 Reporting Quarter So Far *Click Here To Get Our Alerts Faster Via SMS* September 28th Greetings Readers, Two agreements. Under two weeks. Roughly 7.7Mn units of new contracted production for one factory in Athens, Greece. That is the scoreboard Cosmos Health Inc. (Nasdaq: COSM) posted when its Cana Laboratories subsidiary signed five-year agreements with Target Pharma covering approximately 5.2Mn units of a topical antibiotic and an acne treatment. Those contracts pushed Cana's cumulative orderbook past 32.7Mn units, a 31% increase since June. They arrived just days after a separate five-year agreement with Viofar added about 2.5Mn units of ROSARTIA, a rosuvastatin-based cholesterol medicine. Cana's contracted work now spans 11 therapeutic categories, up from nine. Why does that matter? Contract manufacturing turns a plant the company already owns into recurring, scheduled output. According to the Target Pharma announcement, the division is targeted to generate over $10Mn in recurring annual pro-fit at full capacity, with some agreements extending up to ten years. The factory story sits inside a wider turnaround. Cosmos reported record revenue in every 2026 reported quarter, including Q2 revenue of $18.99Mn, up 28.8% year over year, and first-half revenue of $36.91Mn, up 29.7%. Management reaffirmed full-year 2026 guidance of more than $90Mn. The balance sheet moved in the right direction too. Total liabilities fell 13.3% to $40.79Mn in the first half, while shareholders' equity rose 12.2% to $20.67Mn. Then Cosmos repaid its $8Mn ATW convertible note twelve months ahead of maturity, ending further conversions from that instrument. Behind The Numbers: What Management Is Saying COSM CEO Greg Siokas did not dress up the September contract run. Here is how he framed it in the company's orderbook update: “We have added 7.7Mn contracted units this month alone and grown the orderbook 31% since June, and close to threefold since the start of the year.” He went further, noting that established pharmaceutical companies are choosing Cana because it built a facility that meets their standards. His summary line: every agreement "turns infrastructure we have already paid for into long-term, contracted production at attractive margins." Siokas is also putting his own capital behind the plan. The company reports he added more than 7.8Mn shares in 2026, bringing his total holding to 14.6Mn shares. The Pivot: From Distributor To Manufacturer Of Record Cosmos built its name distributing medicines to Greek pharmacies. Today, the manufacturing arm is carrying more of the load. Cana runs a wholly owned 54,000-square-foot facility in Athens, licensed under European Good Manufacturing Practices and certified by the European Medicines Agency. The company has put approximately $5.5Mn into upgrading the site, including a new ACG capsule-filling line. The result is visible in the orderbook. It has grown from over 12Mn units earlier this year to more than 32.7Mn today, with partners such as Pharmex, which signed a five-year agreement for approximately 2.86Mn units. Cosmos Health's operating footprint spans Chicago, Greece, the UK, and Texas. Source: Cosmos Health company presentation Key 2026 figures highlighted by the company. Source: Cosmos Health corporate update via GlobeNewswire About Cosmos Health Inc. (Nasdaq: COSM) Cosmos Health Inc. is a diversified, vertically integrated global heal-thcare group with offices and distribution centers in Greece and the UK. It owns proprietary brands including Sky Premium Life, Mediterranation, bio-bebe, C-Sept, and C-Scrub. The business runs on four engines, per the company's year-to-date update. CosmoFarm supplies pharmacies and posted a record Q2 above $15Mn. Cana Laboratories handles manufacturing. Decahedron nearly doubled UK revenue in Q2. In the U.S., the 18 Series nutraceutical line (Cur18, Liv18, Oliv18 and Fort18) and NOOR Collagen target combined annualized revenue above $22.7Mn. Cosmos has also signed letters of intent to acquire an $11.5Mn pharmacy distribution network and Doc Pharma S.A., an affiliated GMP manufacturer. Sector Watch: Why Contract Manufacturing Draws Attention Pharmaceutical companies increasingly hand production to specialist plants. Precedence Research estimates the global pharmaceutical contract manufacturing market at $194.54Bn in 2025, on a path to approximately $351.55Bn by 2034, a 6.76% compound annual growth rate. The firm expects the small and mid-sized pharmaceutical company segment to expand at the fastest pace. Pharmaceutical contract manufacturing market outlook, 2025 to 2034. Source: Precedence Research For a plant with EU licensing and spare capacity, that backdrop matters. Every new contract spreads fixed costs across more units. 6 Potential Catalysts Putting (Nasdaq: COSM) On Our Watchlist #1. Contracted Orderbook Now Tops 32.7Mn Units. With agreements extending up to ten years, management at (COSM) has long-dated visibility into production volumes at its Athens plant. #2. Record Revenue Delivered In Every 2026 Reporting Period. Q2 revenue climbed 28.8% to $18.99Mn, and (COSM) has reaffirmed full-year 2026 guidance above $90Mn. #3. Convertible Note Retired A Full Year Ahead Of Schedule. By repaying the $8Mn ATW note early and withdrawing its shelf registrations, (COSM) removed a key source of potential dilution. #4. Technical Signals Have Swung Sharply Over The Past Month. Barchart showed 8 of 13 indicators flashing bullish for (COSM) at Friday’s close, with an overall 24% bullish reading versus 100% bearish one month earlier. #5. Insiders Hold More Than One Fifth Of Shares. Yahoo Finance data shows insiders hold approximately 21.68% of (COSM), and the CEO has added more than 7.8Mn shares in 2026. #6. Zacks Coverage Carries A $4.50 Price Target. Zacks Small-Cap Research initiated coverage of (COSM) this year with a $4.50 target. That target hints at a potential upside over 400% from Friday’s close. The Bottom Line Cosmos Health Inc. (Nasdaq: COSM) is building something that is easy to overlook from the outside: contracted, repeatable production inside a factory it already owns. Add record revenue, a lighter balance sheet and a CEO who keeps adding shares, and you have a name worth tracking closely. With a current market capitalization around $36Mn on 9/25/26, and trailing twelve month revenue of about $73.73Mn, per Yahoo Finance, COSM has grabbed our full attention. We’re initiating coverage on Cosmos Health Inc. (Nasdaq: COSM). Be on the lookout for updates heading out shortly. Talk soon. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 09/27/2026 and ending on 09/28/2026 to publicly disseminate information about (COSM:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid thirty five thousand USD ("Funds"). These Funds were part of the twenty five thousand USD funds that TD Media LLC received from a third party named Kilwater Capital LLC who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (COSM:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/cosm-zaizp/#details

SWN Media | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Constant Contact Data Notice